Thompson Davis & CO. Inc. raised its holdings in Athersys, Inc. (NASDAQ:ATHX) by 743.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 64,303 shares of the biopharmaceutical company’s stock after purchasing an additional 56,683 shares during the period. Thompson Davis & CO. Inc. owned approximately 0.06% of Athersys worth $132,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its holdings in Athersys by 345.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 88,561 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 68,680 shares during the period. State Street Corp boosted its holdings in Athersys by 27.2% in the 2nd quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after purchasing an additional 305,944 shares during the period. Royal Bank of Canada boosted its holdings in Athersys by 7,334.0% in the 2nd quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 375,723 shares during the period. Vanguard Group Inc. boosted its holdings in Athersys by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock valued at $6,441,000 after purchasing an additional 366,572 shares during the period. Finally, Northern Trust Corp boosted its holdings in Athersys by 30.8% in the 2nd quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after purchasing an additional 264,549 shares during the period. 19.15% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP John J. Harrington sold 15,000 shares of Athersys stock in a transaction on Monday, September 18th. The shares were sold at an average price of $2.17, for a total value of $32,550.00. Following the transaction, the executive vice president now directly owns 679,416 shares of the company’s stock, valued at $1,474,332.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.40% of the stock is owned by insiders.
ATHX has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a report on Monday, September 18th. Maxim Group set a $12.00 price target on shares of Athersys and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, ValuEngine raised shares of Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Athersys has an average rating of “Hold” and an average target price of $7.17.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $0.96 million. Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.08) EPS.
WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/02/thompson-davis-co-inc-acquires-56683-shares-of-athersys-inc-athx.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
What are top analysts saying about Athersys Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Athersys Inc. and related companies.